Aptose Biosciences Inc. (APTO)

NASDAQ: APTO · Real-Time Price · USD
0.362
-0.010 (-2.58%)
At close: Oct 7, 2024, 4:00 PM
0.370
+0.008 (2.10%)
After-hours: Oct 7, 2024, 4:17 PM EDT
-2.58%
Market Cap 6.66M
Revenue (ttm) n/a
Net Income (ttm) -40.29M
Shares Out 18.11M
EPS (ttm) -3.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 88,963
Open 0.372
Previous Close 0.372
Day's Range 0.353 - 0.372
52-Week Range 0.330 - 3.320
Beta 1.36
Analysts Strong Buy
Price Target 9.00 (+2,383.44%)
Earnings Date Nov 7, 2024

About APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule,... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1986
Employees 36
Stock Exchange NASDAQ
Ticker Symbol APTO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for APTO stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 2,383.44% from the latest price.

Price Target
$9.0
(2,383.44% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Aptose Announces Results from Special Meeting of Shareholders

SAN DIEGO and TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing tuspetini...

4 weeks ago - GlobeNewsWire

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

5 weeks ago - GlobeNewsWire

Aptose Announces Adjournment of its Special Meeting of Shareholders

SAN DIEGO and TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly dif...

7 weeks ago - GlobeNewsWire

Aptose Reports Results for the Second Quarter 2024

TUS+VEN+HMA Triplet Protocol in Frontline Therapy for Newly Diagnosed AML was Reviewed by the FDA and Allowed to Proceed Abstract Supporting Exploration of the TUS+VEN+AZA Triplet in Frontline Therapy...

2 months ago - GlobeNewsWire

Aptose Announces Receipt of Deficiency Notice from Nasdaq

SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly dif...

2 months ago - GlobeNewsWire

Aptose Announces Results from Annual and Special Meeting of Shareholders

SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly dif...

3 months ago - GlobeNewsWire

Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress

TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from oth...

4 months ago - GlobeNewsWire

Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO and TORONTO, June 03, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly dif...

4 months ago - GlobeNewsWire

Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO and TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly diff...

4 months ago - GlobeNewsWire

Aptose Biosciences Inc. (APTO) Q1 2024 Earnings Call Transcript

Aptose Biosciences Inc. (NASDAQ:APTO) Q1 2024 Earnings Conference Call May 14, 2024 5:00 PM ET Company Participants Susan Pietropaolo - MD, Corporate Communications and IR William Rice - Chairman, Pr...

5 months ago - Seeking Alpha

Aptose Reports Results for the First Quarter 2024

TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AM...

5 months ago - GlobeNewsWire

Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024

SAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted ag...

5 months ago - GlobeNewsWire

Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript

Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript

6 months ago - Seeking Alpha

Aptose Reports Results for the Fourth Quarter and Full Year 2023

Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML Tuspetinib Continues Broad Activity Across Mutations with Excellent Safety Profile Luxeptinib G3 Formulation Achieves Desired...

6 months ago - GlobeNewsWire

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024

SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted ...

7 months ago - GlobeNewsWire

Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option

SAN DIEGO and TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) --  Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing highly di...

8 months ago - GlobeNewsWire

Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical

SAN DIEGO and TORONTO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing highly dif...

9 months ago - GlobeNewsWire

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

Reporting Complete Response Data from the Ongoing APTIVATE International Phase 1/2 Study of Tuspetinib (TUS) in Relapsed/Refractory AML Patients TUS Single Agent and TUS/VEN Combination Demonstrate Fa...

10 months ago - GlobeNewsWire

Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

SAN DIEGO and TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly dif...

11 months ago - GlobeNewsWire

Aptose Biosciences Inc. (APTO) Q3 2023 Earnings Call Transcript

Aptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director-Corporate Communications & Investor Relat...

11 months ago - Seeking Alpha

Aptose Reports Results for the Third Quarter 2023

Aptose Reports Results for the Third Quarter 2023 • TUS/VEN Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path

11 months ago - GlobeNewsWire

Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting

SAN DIEGO and TORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly dif...

1 year ago - GlobeNewsWire

Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

Tusp etinib (TUS) Combination with Venetoclax (VEN) Clinical Findings Highlighted   TUS Targets VEN Resistance Mechanisms to Re-sensitize VEN Failure Patients to VEN 44% ORR with TUS/VEN in Difficult-...

1 year ago - GlobeNewsWire

Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023

SAN DIEGO and TORONTO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted ag...

1 year ago - GlobeNewsWire

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

SAN DIEGO and TORONTO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly dif...

1 year ago - GlobeNewsWire